Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety .
Precision BiosciencesFebruary 19, 2021 GMT
DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in
Molecular Therapy describing three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs) following
in vivo gene editing of the
PCSK9 gene with its proprietary ARCUS® genome editing platform.
Molecular Therapy and was led by James M. Wilson, M.D., Ph.D., a professor of Medicine and director of the Penn Gene Therapy Program and the Penn Orphan Disease Center, and Lili Wang, Ph.D., a research director in the Penn Gene Therapy Program and research associate professor of Medicine at the Perelman